U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H21NS.ClH
Molecular Weight 331.903
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DOTHIEPIN HYDROCHLORIDE

SMILES

Cl.CN(C)CC\C=C1/C2=C(CSC3=C1C=CC=C3)C=CC=C2

InChI

InChIKey=XUPZAARQDNSRJB-SJDTYFKWSA-N
InChI=1S/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H/b17-11+;

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8447840 | https://www.drugs.com/uk/dosulepin-capsules-25mg-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/9408183

cis-Dosulepin is a stereoisomer of Dothiepin (trade name Prothiaden, Dothep, Thaden, and Dopress; Dosulepin (INN, BAN) a tricyclic antidepressant that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. Dosulepin is used for the treatment of the major depressive disorder and neuropathic pain. Dosulepin is only Therapeutic Goods Administration and Medicines and Healthcare products Regulatory Agency approved for the treatment of the major depressive disorder. Dothiepin is not used in the United States. The central action of cis-dosulepin was compared with that of its antidepressant stereoisomer trans-dosulepin, cis-dosulepin exerted weaker anti-reserpine, anti-tetrabenazine, and 3H-5-HT (serotonin) uptake inhibiting actions than trans-dosulepin, but cis-dosulepin's inhibition of 3H-dopamine and 3H-norepinephrine uptake was slightly more potent than that of trans-dosulepin. On the other hand, cis-dosulepin exhibited extremely potent anticholinergic action in oxotremorine induced tremor, isolated ileum and the 3H-quinuclidinyl benzilate binding test. It also showed potent apomorphine enhancing the action and shortened the period of immobility in the forced swimming test in animals.

CNS Activity

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 8.4 null [pKi]
Antagonist
2849
 18.0 nM [Kd]
Antagonist
2849
 109.0 nM [Kd]
Antagonist
2849
 38.0 nM [Kd]
Antagonist
2849
 61.0 nM [Kd]
Antagonist
2849
 92.0 nM [Kd]
Inhibitor
8504
 8.6 nM [Kd]
Inhibitor
8504
 46.0 nM [Kd]
Inhibitor
8504
Inhibitor
8504
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Prothiaden

Approved Use

Unknown
Primary
Approved
8583
Prothiaden

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
27.6 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=18
75 mg single, oral
dose: 75 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
17.7 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
29.49 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
51.1 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
84.95 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
117.6 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
458.7 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
576.42 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
961.69 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1586.14 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.4 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
22 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=19 | https://pubmed.ncbi.nlm.nih.gov/6662179/
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
21.58 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
19.33 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.45 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3735103/
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DOTHIEPIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5.6%
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/2/200022_1179027F1025_2_090_1F.pdf#page=20
DOTHIEPIN plasma
Homo sapiens
PubMed

PubMed

TitleDatePubMed
Antidepressant induced cholestasis: hepatocellular redistribution of multidrug resistant protein (MRP2).
2003-02
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
1999-08
Antidepressant drugs and heart electrical field.
1998
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
1997-12-11
Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.
1996
Exacerbation of extrapyramidal symptoms with paroxetine.
1995-09
Extreme suicidality following serotonin syndrome.
1995-09
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics.
1993-06-09
[A case of choreoathetoid movements induced by anticholinergic drugs, trihexyphenidyl HCl and dosulepin HCl].
1992-09
Dothiepin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
1989-07
[Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case].
1986-12
A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.
1984-11
A comparative study of the therapeutic effect and cardiotoxicity of dothiepin HCl and doxepin HCl in reactive depression.
1981
Patents

Patents

JP2011504928A
8
JP2011526251A
112
WO2007136743
3

Sample Use Guides

In Vivo Use Guide
male Slc:Wistar rats: 40 mg/kg, PO
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
DOTHIEPIN HYDROCHLORIDE
MI   USAN  
USAN  
Official Name English
DOSULEPIN HYDROCHLORIDE
EP   JAN   MART.   WHO-DD  
Preferred Name English
DOSULEPIN HYDROCHLORIDE [MART.]
Common Name English
1-PROPANAMINE, 3-DIBENZO(B,E)THIEPIN-11(6H)-YLIDENE-N,N-DIMETHYL-, HYDROCHLORIDE
Systematic Name English
THADEN
Brand Name English
DOTHIEPIN HCL
Common Name English
Dosulepin hydrochloride [WHO-DD]
Common Name English
PROTHIADEN
Brand Name English
DOPRESS
Brand Name English
DOSULEPIN HYDROCHLORIDE [JAN]
Common Name English
DOTHIEPIN HYDROCHLORIDE [USAN]
Common Name English
(E)-3-(DIBENZO(B,E)THIEPIN-11(6H)-YLIDENE)-N,N-DIMETHYLPROPAN-1-AMINE HYDROCHLORIDE
Systematic Name English
NSC-172130
Code English
DOTHEP
Brand Name English
DOSULEPIN HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
DOTHIEPIN HYDROCHLORIDE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID7047778
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
RXCUI
142133
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY RxNorm
EVMPD
SUB01821MIG
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
ChEMBL
CHEMBL1492500
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
FDA UNII
3H0042311V
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
NCI_THESAURUS
C78018
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
212-978-8
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
DRUG BANK
DBSALT001822
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
SMS_ID
100000091934
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
PUBCHEM
6433931
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
MERCK INDEX
m4748
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY Merck Index
CHEBI
31519
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
NSC
172130
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
CAS
897-15-4
Created by admin on Mon Mar 31 17:48:58 GMT 2025 , Edited by admin on Mon Mar 31 17:48:58 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of DOTHIEPIN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966